Stocksigma LogoStocksigma Logo

Curis Lifesciences Reports H1 FY27 Financial Results

Curis Lifesciences reported consolidated revenue from operations of ₹3,703.39 lakhs for the half year ended 30th Sep'26, with net profit attributable to

Curis Lifesciences Reports H1 FY27 Financial Results

Curis Lifesciences Ltd · Outcome · 11 Nov 2026, 6:18 pm

Curis Lifesciences Reports H1 FY27 Financial Results Curis Lifesciences reported consolidated revenue from operations of ₹3,703.39 lakhs for the half year ended 30th Sep'26, with net profit attributable to owners at ₹413.98 lakhs and EPS at ₹5.76. Standalone revenue grew 22.61% YoY to ₹3,411.94 lakhs compared to ₹2,790.89 lakhs in H1 FY26, while standalone PAT declined slightly to ₹413.50 lakhs from ₹421.09 lakhs. During the period, the company expanded operations by acquiring a 51% stake in Uninova Lifesciences and a 49.95% stake in Nigeria-based Curosun Pharmaceutical.

Original exchange filing (PDF)

More announcements from Curis Lifesciences Ltd

All Curis Lifesciences Ltd announcements